Poonam Bhadoria, Manish Kumar Tripathi, Ramanathan Venkatnarayan
preprint
Conformational space of the psychedelic molecule psilocybin was explored. A global minimum was identified and among the several local minima, of the conformers matched with the earlier reported literature. The difference in energy between these two conformers is 9.275 kcal/mol and the rotational barrier is 17.620 kcal/mol. Further properties of these conformers were investigated using FMO, AIM,...
Çağrı Özkurt
preprint
A recent living systematic review in Nature Mental Health found psilocybin reduced depression symptoms across 12 randomized controlled trials, with pooled effect g = 0.90. The original analysis assessed publication bias using Egger’s test, non-significant — but this test has limited power with few studies and cannot produce a bias-corrected estimate. We re-analysed the same open dataset using...
Edward S. Adams
preprint
This Article explores the regulation of the cannabis industry, highlighting its origins, history, and shortcomings. The Article then compares the cannabis and psilocybin industries, arguing against the replication of the cannabis regulatory structure for psilocybin. Instead, this Article will propose tailored regulatory solutions designed to address the unique characteristics of psilocybin and...
Christopher P. Albertyn, Jérémie Richard, Ron Joseph Shore et al.
preprint
Demoralization syndrome (DS) - a distinct clinical entity characterized by helplessness, hopelessness, and a persistent loss of meaning - affects approximately one in five Canadians with advanced cancer and is associated with increased desire for hastened death, negative clinical outcomes, and higher economic burden, yet recognition and treatment of DS remains suboptimal in modern oncology....
SSRN Electronic Journal
Robin Sandell, Adele Lafrance, Olivia Gosseries et al.
preprint
Current spinal cord injury treatments primarily manage symptoms rather than promote neurological recovery. Psilocybin enhances neuroplasticity through 5-HT2A agonism and brain-derived neurotrophic factor upregulation, suggesting therapeutic potential for spinal cord injury rehabilitation. We conducted semi-structured interviews with three individuals who had incomplete spinal cord injuries...
Julia Etkin, Vincent Joralemon
preprint
Psilocybin is currently classified as a Schedule I controlled substance under the Controlled Substances Act-the federal designation reserved for substances deemed to have no accepted medical use and a high potential for abuse. Yet by comparative-harm metrics, psilocybin ranks among the safest psychoactive compounds in widespread use, far safer than alcohol and tobacco, both of which are...
Journal of Psychopharmacology
October 27, 2026
José Augusto Silva Reis, Lara Zancaner Ueta, José Carlos Bouso et al.
This systematic review evaluates the relationship between classical psychedelic drugs (D-Lysergic acid N,N-diethylamide, psilocybin, ayahuasca/N-N-dimethyl-tryptamine, and mescaline) and the emergence of psychotic symptoms, aiming to synthesize evidence from contemporary studies (1984-2025) regarding the risk factors, prevalence, and clinical characteristics of psychosis related to psychedelic...
Psychopharmacology
October 19, 2026
Landon M. Klein, Jared M. Kopelman, Richard F Sharp et al.
Classical psychedelic drugs such as the tryptamine psilocybin can alter temporal perception. Previously, the phenylethylamine psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI), a 5-HT2A receptor agonist, altered timing precision and accuracy in mice performing the discrete-trials temporal discrimination task (TDT), a retrospective timing task where subjects differentially respond depending on...
Frontiers in Psychiatry
October 14, 2026
Mathieu Seynaeve, Leonie Schneider, Ian Roullier et al.
BackgroundWhile psychedelic treatments for difficult-to-treat mental health conditions are advancing, participant perspectives remain under-explored. This study examined former participants’ experiences across recruitment, preparation, dosing, integration and study ending, and generated recommendations for future trials and treatment delivery.MethodsThis qualitative descriptive study, informed...
Orvosi hetilap
September 13, 2026
Szabolcs Kéri
Over the past five years, the literature on the psychiatric use of psychedelic and related treatments has expanded substantially. Several randomized controlled trials and pooled analyses have been conducted in mood disorders, treatment-resistant depression, and post-traumatic stress disorder. Trial methodology, however, remains a fundamental source of uncertainty, and despite the popularity of...